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Objective: To determine the cost-effectiveness of several external beam radiation treat-
ment modalities for the treatment of patients with localized prostate cancer. Methods:
A lifetime Markov model incorporated the probabilities of experiencing treatment-related
long-term toxicity or death.Toxicity probabilities were derived from published sources using
meta-analytical techniques. Utilities and costs in the model were obtained from publicly
available secondary sources. The model calculated quality-adjusted life expectancy and
expected lifetime cost per patient, and derived ratios of incremental cost per quality-
adjusted life year (QALY) gained between treatments. Analyses were conducted from both
payer and societal perspectives. One-way and probabilistic sensitivity analyses were per-
formed. Results: Compared to intensity-modulated radiation therapy (IMRT) and proton
beam therapy (PT), stereotactic body radiation therapy (SBRT) was less costly and resulted
in more QALYs. Sensitivity analyses showed that the conclusions in the base-case sce-
nario were robust with respect to variations in toxicity and cost parameters consistent
with available evidence. At a threshold of $50,000/QALY, SBRT was cost-effective in 75%
and 94% of probabilistic simulations compared to IMRT and PT, respectively, from a payer
perspective. From a societal perspective, SBRT was cost-effective in 75% and 96% of
simulations compared to IMRT and PT, respectively, at a threshold of $50,000/QALY. In
threshold analyses, SBRT was less expensive with better outcomes compared to IMRT
at toxicity rates 23% greater than the SBRT base-case rates. Conclusion: Based on the
assumption that each treatment modality results in equivalent long-term efficacy, SBRT is
a cost-effective strategy resulting in improved quality-adjusted survival compared to IMRT
and PT for the treatment of localized prostate cancer.
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INTRODUCTION
The National Cancer Institute estimates that 241,740 new cases
of prostate cancer will be diagnosed in 2012, along with 28,170
deaths (National Cancer Institute, 2012). The Prostate Cancer
Outcomes Study (PCOS), which was initiated by the National
Cancer Institute in 1994, noted that 88% of the newly diagnosed
prostate cancer cases will be localized disease. Based on a review
of the current published literature, there are several options for
patients diagnosed with clinically localized prostate cancer includ-
ing active surveillance, surgery, and radiation therapy. In 2010, the
Agency for Healthcare Research and Quality (AHRQ) concluded
that insufficient evidence exists to fully assess the superiority of
one type of radiation therapy over another for the treatment of
localized prostate cancer (Agency for Healthcare Research and
Quality, 2010). The objective of this study is to address this gap
by developing a decision analysis model that integrates currently
available published evidence on the post-treatment incidence of
long-term toxicities to compare the incremental cost-effectiveness
of three modern external beam radiation therapies for localized
prostate cancer: intensity-modulated radiation therapy (IMRT),
proton beam therapy (PT), and stereotactic body radiation therapy
(SBRT).
Intensity-modulated radiation therapy, which is a commonly
used treatment for patients with localized prostate cancer, involves
the external delivery of multiple beams of radiation that con-
form to the shape of the tumor, and where the intensity of each
beam can be modulated in order to spare surrounding healthy
tissue. IMRT therapy is typically delivered in 40 fractions (i.e.,
treatment sessions) and requires 8–9 weeks of treatment. PT is
delivered externally to a predefined depth, potentially with little
radiation delivered beyond that point, thus sparing surrounding
healthy tissue. Like IMRT, PT typically is delivered in 40 frac-
tions and requires 8–9 weeks of treatment. A study conducted
by Konski et al. (2007) found that PT was not a cost-effective
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treatment option for localized prostate cancer when compared to
IMRT.
Stereotactic body radiation therapy is the use of accurate and
image-guided radiation therapy to treat tumors using up to five
intense radiation treatments (Martin and Gaya, 2010). Because
a higher dose is given in each fraction, image guidance during
treatment and an ability to adjust for tumor/target motion is
important in order to minimize treatment-related toxicity. Recent
studies have indicated that SBRT toxicity levels are comparable
to those of other radiation treatment options (Sanda et al., 2008;
Chen et al., 2009; Townsend et al., 2011), with long-term (5-year)
progression-free survival at 93% (Freeman and King, 2011).
In the current paper we present a Markov model developed to
estimate the comparative long-term incremental cost-effectiveness
of IMRT, PT, and SBRT. The analyses are conducted using a life-
time horizon from both the perspective of a health care payer as
well as a societal perspective that includes the value of patients’
time spent in treatment.
MATERIALS AND METHODS
OVERVIEW
Decision-analytic techniques involved analysis of a lifetime cohort
Markov model, programmed in Microsoft® Excel, to assess the
cost-effectiveness of three radiation treatment modalities for local-
ized prostate cancer: SBRT, IMRT, and PT. Brachytherapy was not
included as a comparator in the model because the method of
delivery (i.e., requiring anesthesia and invasive) was considered to
be significantly different from SBRT, IMRT, and PT. Furthermore,
because of the anesthesia requirement, some studies have shown
that brachytherapy is more likely to be used with younger men
when compared with external beam radiation (Sanda et al., 2008;
Chen et al., 2009).
Depending on the treatment selected, patients in the model are
at risk of experiencing one or more of three types of treatment-
related long-term toxicity, or death. Long-term toxicities included
in the analysis were gastrointestinal (GI), genitourinary (GU),
and sexual dysfunction (SD). Long-term toxicity is defined as
adverse events= grade 2, using the Radiation Therapy Oncology
Group (RTOG) scale≥12 months following treatment. The model
assumes that patients can experience treatment-related long-term
toxicity within the first year following treatment and are at risk to
continue to experience it throughout their lives. Figure 1 illustrates
the Markov states and transitions that can occur in the model. The
model includes eight health states that reflect all possible combi-
nations of the three long-term toxicity states (no toxicity, GI only,
GU only, SD only, GI & GU, GI & SD, GU & SD, GI & GU & SD).
Since data were not available regarding the duration of side effects,
the assumption in the model is that during each Markov cycle
patients remain in the same Markov health state or die. Measures
of utility (an overall quality of life measure on a 0 to 1 scale) and
cost are assigned to each state. Treatment-specific mortality and
long-term annual mortality rates with localized prostate cancer are
based on published sources and data from SEER, respectively. The
model assumes that the long-term disease control is comparable
across the treatments, which is consistent with currently available
literature.
In the base-case we assume that all toxicities are associated
with a one-time cost. Analysis of quality-adjusted survival with
the Markov model involves tracking patients according to whether
or not they experience each of the types of long-term toxicity, and
weighting their years of survival by the utility associated with their
corresponding toxicity state. The model calculates the quality-
adjusted life years (QALYs) and costs per patient over the course
of a lifetime. Analyses were performed from a healthcare payer
perspective. An additional analysis was conducted from a societal
perspective that included the forgone value of patients’ time spent
in initial radiation treatment.
MODEL PARAMETERS AND DATA SOURCES
The model population consists of 65-year-old males with local-
ized prostate cancer who declined or were ineligible for surgery
and are eligible for external radiation therapies. Model parameters
and data sources are summarized in Tables 1–5, and are described
below.
Long-term toxicity and mortality
The probability of experiencing each type of treatment-related
long-term toxicity was derived using meta-analytic techniques.
FIGURE 1 | Markov model. GI, gastrointestinal; GU, genitourinary; SD, sexual dysfunction.
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A search was conducted in MEDLINE, EMBASE, PsycINFO,
and PubMed for studies published between 1998 and 2010 that
reported GU, GI, and SD toxicities over a given period of time.
Table 1 displays the characteristics of the 10 studies that were cho-
sen for the meta-analysis. Due to a lack of randomized controlled
trials, all 10 studies were either clinical trials with no control group
or observational studies with a single cohort. The meta-analysis
used a random-effects model to minimize heterogeneity across
studies due to clinical or methodological differences. Furthermore,
the meta-analysis used the normally distributed log odds ratio as
the outcome variable, after which the pooled log odds ratio was
converted back to an annual rate.
Table 2 displays the treatment-related probabilities of experi-
encing the various types of long-term toxicity and mortality. A
recent paper published by Coen et al. (2012) suggests that PT toxi-
city has changed very little in the last 10 years. Also, in the absence
of long-term SD toxicity rates for PT, in the base-case, the SD rates
were assumed to be equal to IMRT because the method of deliv-
ery over time was similar – i.e., small doses over a long period
of time. An age-specific mortality rate for prostate cancer patients
was applied to all patients in the model using SEER data (Altekruse
et al., 2010). The risk of dying from treatment (IMRT, SBRT, and
PT) was assumed to be zero.
Health-related quality of life
Quality-adjusted life expectancy associated with each treatment
was estimated using utilities assigned to each health state in the
model (Table 3). Utilities are weights that quantify health-related
Table 1 | Characteristics of the 10 studies chosen for the meta-analysis.
Treatment Study Sample size Follow-up
time (months)
Age (range) Toxicity studied
SBRT Friedland et al. (2009) 112 24 Mean 70 (55–87) SD
Katz et al. (2010) 206 17 (dose 36.25) Mean 69 (45–88) GU, GI, SD
30 (dose 35)
King et al. (2009) 41 33 Median 66 (48–83) GU, GI
Wiegner and King (2010) 20 35.5 Median 68 (57–83) SD
IMRT Kirichenko et al. (2006) 928 36 NA GU, GI
Zelefsky et al. (2002) 772 36 Median 69 (46–86) GU, GI, SD
Zelefsky et al. (2006) 561 96 Median 68 (46–86) GU, GI, SD
PT Schulte et al. (2000) 870 36 NA GU, GI
Slater et al. (1998) 643 36 NA GU, GI
Slater et al. (1999) 315 36 NA GU, GI
GI, gastrointestinal; GU, genitourinary; IMRT, intensity-modulated radiation therapy; NA, not available; PT, proton beam therapy; SBRT, stereotactic body radiation
therapy; SD, sexual dysfunction.
Table 2 |Treatment-related mortality and long-term toxicity.
Probabilities Base-case default value SE Source
TREATMENT-RELATED MORTALITY
SBRT 0.000 – Assumption
IMRT 0.000 – Assumption
PT 0.000 – Assumption
LONG-TERMTOXICITIES – SBRT
GU 0.040 0.023 Friedland et al. (2009), Katz et al. (2010), King et al. (2009)
GI 0.027 0.010 Katz et al. (2010), King et al. (2009)
SD 0.159 0.088 Friedland et al. (2009), Katz et al. (2010), Wiegner and King (2010)
LONG-TERMTOXICITIES – IMRT
GU 0.035 0.016 Kirichenko et al. (2006), Zelefsky et al. (2002), Zelefsky et al. (2006)
GI 0.013 0.008 Kirichenko et al. (2006), Zelefsky et al. (2002), Zelefsky et al. (2006)
SD 0.272 0.232 Zelefsky et al. (2002), Zelefsky et al. (2006)
LONG-TERMTOXICITIES – PT
GU 0.019 0.004 Schulte et al. (2000), Slater et al. (1998), Slater et al. (1999)
GI 0.015 0.006 Schulte et al. (2000), Slater et al. (1999)
SD 0.272 0.232 Assume the same as IMRT
GI, gastrointestinal; GU, genitourinary; IMRT, intensity-modulated radiation therapy; PT, proton beam therapy; SBRT stereotactic body radiation therapy; SD, sexual
dysfunction; SE, standard error.
An RTOG (Radiation Therapy Oncology Group) scale was used to measure toxicity in all but the Kirichenko et al., 2006; scale not reported) and Zelefsky et al., 2006;
CTCAE scale) studies.
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quality of life (HRQoL) on a scale from 0 to 1, where 0 reflects
death and 1 reflects perfect health. The QALYs associated with each
of the long-term toxicity health states were estimated using utility
weights derived from Stewart et al. (2005). The utility value for not
experiencing treatment-related long-term toxicity was assumed
to be 1, and the utility value for death was 0. QALYs in each
Markov state and cycle were determined by multiplying the utility
Table 3 | Model utility inputs.
Utility parameters Base-case
default value
SE Source
No long-term toxicities 1.00 0.00 Assumption
GU 0.83 0.02 Stewart et al. (2005)
GI 0.71 0.02 Stewart et al. (2005)
SD 0.89 0.01 Stewart et al. (2005)
GU & GI 0.70 0.04 Stewart et al. (2005)
GU & SD 0.79 0.03 Stewart et al. (2005)
GI & SD 0.57 0.04 Stewart et al. (2005)
GU & GI & SD 0.45 0.04 Stewart et al. (2005)
Death 0.00 0.00 By definition
GI, gastrointestinal; GU, genitourinary; SD, sexual dysfunction; SE, standard error;
QALYs in each Markov state and cycle are determined by the product of the base-
line age-specific background utility for males (Hamner et al., 2006) and the utility
associated with long-term toxicities.
associated with each of the long-term toxicities by a baseline age-
specific background utility for males in the general population
(Hamner et al., 2006).
Resource utilization
Table 4 displays the base-case resource utilization parameter val-
ues for each treatment, including the numbers of routine and
toxicity-related office visits and treatments, and the number of
patient hours lost due to treatment. The resource utilization para-
meter values were used to estimate treatment-related costs in the
model.
Costs
Table 5 displays the unit costs per unit of resource utilization that
were used in the model. All unit costs in the table reflect Medicare
payments. The SBRT treatment cost was based on nationally
unadjusted Medicare rates using codes for robotic SBRT, and the
remaining treatment costs were based on published sources. For
the societal perspective, the age-specific cost per hour of time lost
in treatment was based on 2011 estimates from the Bureau of Labor
Statistics (2011). Additional patient costs, such as transportation
costs, are not included in the societal perspective. From a lost
work time perspective, we assumed that this wage value reflects
the opportunity cost of time for both working and retired persons
of the same age. The cost of routine monitoring and toxicity-
related costs was applied annually for GU and SD whereas for GI
a one-time cost was applied assuming that GI symptoms are less
Table 4 | Model resource utilization inputs.
Utilization parameters Value Source
TREATMENT-RELATED (PERTREATMENT)
SBRT
Work-time lost (hours per treatment) 10 Expert opinion
IMRT
Work-time lost (hours per treatment) 90 Ollendorf et al. (2009)
PT
Work-time lost (hours per treatment) 100 Ollendorf et al. (2008)
ROUTINE MONITORING (PERYEAR)
Office visit (1st year) 2 Expert opinion
Office visit (subsequent years) 1 Expert opinion
PSA 2 Expert opinion
TOXICITY-RELATED
GU toxicity (per year)
Routine office visit 2 Expert opinion
Pharmacologic treatment (oxybutynin) 365 Daily dosage based on package insert
Cystoscopy 1 Expert opinion
GI toxicity (one-time utilization)
Routine office visit 2 Assumption
Enema (additional colonoscopy and sigmoidoscopy if needed)* 1 Assume one-time treatment for GI toxicity
SD toxicity (per year)
Pharmacologic treatment (sildenafil) 22 Cooke et al. (2005)
GI, gastrointestinal; GU, genitourinary; IMRT, intensity-modulated radiation therapy; PSA, prostate specific antigen; PT, proton beam therapy; SBRT, stereotactic body
radiation therapy; SD, sexual dysfunction.
*Patients experiencing late GI toxicity were first treated with a 6-month course of enema in 70% of the cases. The remaining patients were assumed to undergo a
colonoscopy followed by an average of three sigmoidoscopies and an additional 6-month course of enema. The cost is calculated as a one-time weighted average
cost.
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Table 5 | Model cost inputs.
Cost parameters Value Source
TREATMENT COST
SBRT $20,889 Medicare rates – data on file, Accuray Inc.
IMRT $28,805 Konski et al. (2006), MAG Mutual (2011)
PT $65,250 Ollendorf et al. (2008)
Work-time lost (cost per hour) $20 Bureau of Labor Statistics (2011)
ROUTINE MONITORING
Urologist $177 MAG Mutual (2011)
Office visit $102 MAG Mutual (2011)
PSA $103 MAG Mutual (2011)
TOXICITY-RELATED
GU toxicity
Daily pharmacologic treatment (oxybutynin) $1 Red Book (2010)‡
Cystoscopy $214 MAG Mutual (2011)
GI toxicity
Enema (additional colonoscopy and sigmoidoscopy if needed)* $259† MAG Mutual (2011), Red Book (2010)‡
SD toxicity
Daily pharmacologic treatment (sildenafil) $12 Red Book (2010)‡
GI, gastrointestinal; GU, genitourinary; IMRT, intensity-modulated radiation therapy; PSA, prostate specific antigen; PT, proton beam therapy; SBRT, stereotactic body
radiation therapy; SD, sexual dysfunction.
*Patients experiencing late GI toxicity were first treated with a 6-month course of enema in 70% of the cases. The remaining patients were assumed to undergo a
colonoscopy followed by an average of three sigmoidoscopies and an additional 6-month course of enema. The cost is calculated as a one-time weighted average
cost.
†Assumes one-time treatment cost.
‡Costs are inflated to 2011 values based on the Consumer Price Index (Bureau of Labor Statistics, 2011).
likely to be chronic. All costs were based on published sources and
costs used in the analysis are expressed in 2011 US dollars, with
costs and utilities discounted at 3.0% annually.
ANALYSES
Base-case model
Lifetime costs and QALYs per patient were calculated for each
treatment. Lifetime costs were calculated by summing all costs
associated with each health state that patients spend time in, and
QALYs are calculated by summing the product of utilities associ-
ated with each health state and the time spent in the health state.
The incremental cost-effectiveness ratio (ICER) value was calcu-
lated by first rank-ordering the treatment regimens by increasing
cost and then comparing each strategy to the next less costly
strategy by dividing the additional cost by additional benefit
(QALY).
Sensitivity analyses
One-way sensitivity analysis was conducted to determine the para-
meters to which the ICER is most sensitive. One-way sensitivity
analyses were performed by varying selected model parame-
ters based on the 95% confidence interval (CI) of the base-case
estimate, where available, while keeping all other parameters con-
stant. CIs were not available for the costs used in the model, and so
they were varied through a range of 75%–125% of the base-case
estimate while keeping all other parameters constant. Probabilis-
tic sensitivity analysis was also conducted to assess uncertainty in
the cost-effectiveness analysis by determining the probability of
a treatment being cost-effective at a threshold of $50,000/QALY.
The probability estimates for toxicity and utility were assumed
to follow a beta distribution [see Tables 2 and 3 for the standard
errors (SE)], and cost parameters were assumed to follow a gamma
distribution and the SE was calculated as 50% of the base-case
default value.
An alternative cost scenario was tested by applying an annual
cost for treating GI toxicity, instead of the one-time costs used in
the base-case. In the absence of a SD toxicity rate for PT, an alter-
native toxicity scenario was tested by setting the SD toxicity for PT
equal to SBRT. Finally, in threshold analyses, the toxicity of SBRT
was varied from the base-case assumption to assess the impact of
alternate toxicity rates on base-case results.
RESULTS
BASE-CASE MODEL
Table 6 displays the results of the cost-effectiveness analyses from
the payer and societal perspectives.
Payer perspective
SBRT was the least expensive option in terms of lifetime costs
($24,873), followed by IMRT ($33,068) and PT ($69,412). IMRT
and PT were both more costly and yielded fewer QALYs when com-
pared with SBRT (total QALYs: 8.11, 8.05, 8.06 for SBRT, IMRT,
PT, respectively).
Societal perspective
When the value of lost time in treatment was included, SBRT
remained the least expensive treatment option ($25,097), followed
by IMRT ($35,088) and then PT ($71,657). Once again, IMRT and
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Table 6 | Cost-effectiveness results for all comparator treatments for
the base-case.
Total per patient Incremental ICER Costs/
QALY gained
Costs QALYs Costs QALYs
PAYER PERSPECTIVE
SBRT $24,873 8.11 – – Reference
IMRT $33,068 8.05 $8,195 −0.062 Dominated*
PT $69,412 8.06 $44,539 −0.047 Dominated
SOCIETAL PERSPECTIVE†
SBRT $25,097 8.11 – – Reference
IMRT $35,088 8.05 $9,991 −0.062 Dominated
PT $71,657 8.06 $46,560 −0.047 Dominated
ICER, incremental cost-effectiveness ratio; IMRT, intensity-modulated radiation
therapy; QALY, quality-adjusted life year.
NOTE: Results are estimated for a patient 65 years old using Medicare reimburse-
ment rates.
*Dominated – higher cost and lower QALY.
†Societal perspective also includes productivity costs owing to time spent in
treatment.
PT were both dominated by SBRT because they were more costly
and yielded fewer QALYs when compared with SBRT (total QALYs:
8.11, 8.05, 8.06 for SBRT, IMRT, PT, respectively).
SENSITIVITY ANALYSES
When the toxicity parameters were varied based on their CIs, and
the costs by ±25%, the results did not change from the base-case
in both payer and societal perspectives; SBRT was the domi-
nant strategy, being less expensive with more QALYs compared
to IMRT and PT. The probabilities of SBRT being cost-effective
at $50,000/QALY from both the payer and societal perspective are
presented in Table 7. The probabilities of SBRT being cost-effective
compared to IMRT and PT are 75.1% and 94.1%, respectively,
from the payer perspective; 75.1% and 95.5%, respectively, from
the societal perspective. Figure 2 displays the probabilities of SBRT
being cost-effective compared to IMRT and PT, from the payer
(Figure 2A) and societal (Figure 2B) perspective.
The alternative cost scenario analysis using an annual cost for
treating GI toxicity, instead of the one-time costs used in the base-
case model, produced results that were similar to the base-case.
Both IMRT and PT remained more costly and yielded fewer QALYs
when compared with SBRT from either perspective. Also, Table 8
displays the results of an alternative toxicity scenario where SD
toxicity for PT was set equal to SBRT, in contrast to the base-case
model which set PT equal to IMRT. When the SD toxicity for PT
was set equal to SBRT, then SBRT weakly dominates IMRT and no
longer dominates PT.
In threshold analyses, when all three toxicity rates for SBRT
were increased by 23% from the base-case, the total lifetime costs
for SBRT was lower than for IMRT ($25,037 versus $33,068), and
the QALYs for SBRT were slightly higher than for IMRT (8.051
versus 8.049). If all three toxicity rates for SBRT were increased by
≥24%, the QALYs for SBRT are lower than for IMRT. Furthermore,
the threshold analyses showed that IMRT was only cost-effective
Table 7 | Probability of SBRT being cost-effective at the $50,000/QALY
threshold.
SBRT Comparator Payer perspective
$50,000/QALY
Societal perspective
$50,000/QALY
IMRT 75.1% 75.1%
PT 94.1% 95.5%
IMRT, intensity-modulated radiation therapy; PT, proton beam therapy; QALY,
quality-adjusted life year; SBRT, stereotactic body radiation therapy.
Table 8 | Alternative sensitivity analysis with proton therapy toxicity
set equal to SBRT toxicity.
Total per patient Incremental ICER Costs/
QALY gained
Costs QALYs Costs QALYs
PAYER PERSPECTIVE
SBRT $24,873 8.11 – – Reference
IMRT $33,068 8.05 $8,195 −0.062 Weakly dominated*
PT $69,094 8.17 $44,221 0.057 $13,755,207
SOCIETAL PERSPECTIVE†
SBRT $25,097 8.11 – – Reference
IMRT $35,088 8.05 $9,991 −0.062 Weakly dominated
PT $71,339 8.17 $46,242 0.057 $14,383,693
ICER, incremental cost-effectiveness ratio; IMRT, intensity-modulated radiation
therapy; PT, proton beam therapy; QALY, quality-adjusted life year; SBRT, stereo-
tactic body radiation therapy.
NOTE: Results are estimated for a patient 65 years old using Medicare reimburse-
ment rates.
*Dominated – higher cost and lower QALY.
†Societal perspective also includes productivity costs owing to time spent in
treatment.
compared to SBRT at a $100,000/QALY threshold when all three
toxicity rates for SBRT were increased by 54% from the base-case
rates, from a payer’s perspective. Similarly, from a societal perspec-
tive, IMRT was only found to be cost-effective at a $100,000/QALY
threshold when the toxicity rates of SBRT were increased by at
least 61% from the base-case rates.
Among the three toxicities included in the model, the SD toxi-
city rate for SBRT was found to be lower than for IMRT. If the SD
toxicity rate for SBRT is increased by more than 43% from the base-
case rate, then the QALY for SBRT was lower than for IMRT. From
a payer’s perspective, the threshold analyses showed that IMRT was
only cost-effective compared to SBRT at a $100,000/QALY thresh-
old when the SD toxicity rate for SBRT was increased by 97% from
the base-case rate. Similarly, from a societal perspective, IMRT
was only cost-effective compared to SBRT at a $100,000/QALY
threshold when the SD toxicity rate for SBRT was increased by
109% from the base-case rate.
DISCUSSION
In this study, we found that SBRT was less expensive than both
IMRT and PT, with SBRT patients expecting to have a better
quality of life owing to its more favorable toxicity profile. The
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FIGURE 2 | Probability of SBRT being cost-effective when compared to IMRT and ProtonTherapy, from the Payer (A) and Societal (B) Perspective.
Note: the cost-effectiveness acceptability curve shows the percentage of iterations in the probabilistic sensitivity analysis that are cost-effective at a certain
threshold.
probabilistic sensitivity analyses from both the payer and soci-
etal perspectives showed that, compared to the other treatments,
SBRT is cost-effective at a $50,000/QALY threshold in 75%–96%
of model simulations.
There is a continued trend of increasing utilization of more
costly treatments for localized prostate cancer. From 2000 to
2008, the use of IMRT over the older 3D conformal radiation
has increased from 28.7% to 81.7% (Nguyen et al., 2011). Since
2008, there has been an exponential increase in the number of
proton facilities built in the United States – each of which costs
approximately $200 million – with a corresponding increase in its
use for prostate cancer treatment. Cost-effectiveness is one way
to examine the “value” of different treatment options. Consistent
with prior findings by Konski et al. (2007), we also demonstrate
that proton therapy is unlikely to be cost-effective. Importantly,
we find that newer technology does not always equate to cost-
lier treatment. SBRT, because of an ability to shorten radiation
treatment to five fractions, results in cost savings compared to
IMRT and PT. If longer-term follow-up continues to demon-
strate favorable toxicity and disease control outcomes for SBRT,
then this study provides important data which may have policy
implications.
This study has several limitations worth mentioning. There
are limited data on SBRT for localized prostate cancer. In fact,
since this study began, reports from five additional SBRT studies,
each with varying numbers of patients and months of follow-up,
have been published (Aluwini et al., 2010; Bolzicco et al., 2010;
Kang et al., 2011; Townsend et al., 2011; Jabbari et al., 2012).
None of these studies reached conclusions that differ substantially
from the assumptions used in the present analysis (i.e., toxicity
remains relatively low and disease control mirrors that obtained
with other radiation therapy options). Further, the published liter-
ature on SBRT of localized prostate cancer has consisted mostly of
patients treated with the CyberKnife Robotic Radiosurgery System
(Accuray Incorporated, Sunnyvale, CA, USA; Friedland et al., 2009;
King et al., 2009, 2012; Katz et al., 2010; Freeman and King, 2011).
Two studies have been published which used conventional linear
accelerators to deliver prostate SBRT (Madsen et al., 2007; Boike
et al., 2011), but both used lower doses compared to current SBRT
standards and therefore were not included in the model estimates.
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Inclusion of toxicity results from studies that used lower doses of
SBRT may bias our results further in favor of SBRT. There is also a
lack of data on the median time to resolution of long-term toxicity.
Therefore, in the model, patients who develop long-term toxicity
were assumed to remain in a health state reflective of their toxicity
until they die.
In conclusion, based on the assumption that each treatment
modality results in equivalent long-term disease control, results
from this study suggest that SBRT is cost-effective, resulting
in cost savings and improved quality-adjusted survival com-
pared to IMRT and PT for the treatment of localized prostate
cancer. Additional studies are needed to directly examine the
comparative effectiveness of the different radiation treatments
for localized prostate cancer. Given the lack of randomized
trial data, this study provides important and novel informa-
tion based on currently available published evidence, and con-
tributes to an understanding of the comparative value of three
types of external beam radiation treatments for localized prostate
cancer.
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